Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Mark H Townsend & Erich J Conrad. (2007) The therapeutic potential of escitalopram in the treatment of panic disorder. Neuropsychiatric Disease and Treatment 3:6, pages 835-838.
Read now
Read now
Dawson W Hedges & Fu Lye M Woon. (2007) An emerging role for escitalopram in the treatment of obsessive-compulsive disorder. Neuropsychiatric Disease and Treatment 3:4, pages 455-461.
Read now
Read now
Borwin Bandelow, Dirk Wedekind & Teresa Leon. (2007) Pregabalin for the treatment of generalized anxiety disorder: a novel pharmacologic intervention. Expert Review of Neurotherapeutics 7:7, pages 769-781.
Read now
Read now
Michael E Thase. (2006) Managing depressive and anxiety disorders with escitalopram. Expert Opinion on Pharmacotherapy 7:4, pages 429-440.
Read now
Read now
Articles from other publishers (17)
Ai-shan Su, Jun-wei Zhang & Jing Zou. (2019) The anxiolytic-like effects of puerarin on an animal model of PTSD. Biomedicine & Pharmacotherapy 115, pages 108978.
Crossref
Crossref
Arash Mowla, Farzaneh Modarresi & Seyed Ali Dastgheib. (2018) Comparing escitaloipram with sertraline for obsessive and compulsive symptoms in patients with obsessive compulsive disorder: A comparative double blind clinical trial. Asian Journal of Psychiatry 38, pages 92-95.
Crossref
Crossref
Jeesun Jung, Elisabeth A. Tawa, Christine Muench, Allison D. Rosen, Karl Rickels & Falk W. Lohoff. (2017) Genome-wide association study of treatment response to venlafaxine XR in generalized anxiety disorder. Psychiatry Research 254, pages 8-11.
Crossref
Crossref
Ruben Vardanyan & Victor Hruby. 2016. Synthesis of Best-Seller Drugs. Synthesis of Best-Seller Drugs
111
143
.
S. Doria, A. de Vuono, R. Sanlorenzo, F. Irtelli & C. Mencacci. (2015) Anti-anxiety efficacy of Sudarshan Kriya Yoga in general anxiety disorder: A multicomponent, yoga based, breath intervention program for patients suffering from generalized anxiety disorder with or without comorbidities. Journal of Affective Disorders 184, pages 310-317.
Crossref
Crossref
Li-Ming Zhang, Zhi-Kun Qiu, Nan Zhao, Hong-Xia Chen, Yan-Qin Liu, Jiang-Ping Xu, You-Zhi Zhang, Ri-Fang Yang & Yun-Feng Li. (2014) Anxiolytic-like effects of YL-IPA08, a potent ligand for the translocator protein (18 kDa) in animal models of post-traumatic stress disorder. The International Journal of Neuropsychopharmacology 17:10, pages 1659-1669.
Crossref
Crossref
Stuart A. Montgomery, Julie C. Locklear, Henrik Svedsäter & Hans Eriksson. (2014) Efficacy of once-daily extended release quetiapine fumarate in patients with different levels of severity of generalized anxiety disorder. International Clinical Psychopharmacology 29:5, pages 252-262.
Crossref
Crossref
Alissa J. Cooper, Sneha Narasimhan, Karl Rickels & Falk W. Lohoff. (2013) Genetic polymorphisms in the PACAP and PAC1 receptor genes and treatment response to venlafaxine XR in generalized anxiety disorder. Psychiatry Research 210:3, pages 1299-1300.
Crossref
Crossref
F W Lohoff, S Narasimhan & K Rickels. (2012) Interaction between polymorphisms in serotonin transporter (SLC6A4) and serotonin receptor 2A (HTR2A) genes predict treatment response to venlafaxine XR in generalized anxiety disorder. The Pharmacogenomics Journal 13:5, pages 464-469.
Crossref
Crossref
Alissa J. Cooper, Karl Rickels & Falk W. Lohoff. (2013) Association analysis between the A118G polymorphism in the OPRM1 gene and treatment response to venlafaxine XR in generalized anxiety disorder. Human Psychopharmacology: Clinical and Experimental 28:3, pages 258-262.
Crossref
Crossref
F W Lohoff, T D Aquino, S Narasimhan, P K Multani, B Etemad & K Rickels. (2011) Serotonin receptor 2A (HTR2A) gene polymorphism predicts treatment response to venlafaxine XR in generalized anxiety disorder. The Pharmacogenomics Journal 13:1, pages 21-26.
Crossref
Crossref
Trevor Archer, Serafino Ricci & Max Rapp Ricciardi. 2013. Omics for Personalized Medicine. Omics for Personalized Medicine
309
334
.
Sneha Narasimhan, Tiffany D. Aquino, Pushpinder K. Multani, Karl Rickels & Falk W. Lohoff. (2012) Variation in the catechol-O-methyltransferase (COMT) gene and treatment response to venlafaxine XR in generalized anxiety disorder. Psychiatry Research 198:1, pages 112-115.
Crossref
Crossref
Sneha Narasimhan, Tiffany D. Aquino, Rachel Hodge, Karl Rickels & Falk W. Lohoff. (2011) Association analysis between the Val66Met polymorphism in the brain-derived neurotrophic factor (BDNF) gene and treatment response to venlafaxine XR in generalized anxiety disorder. Neuroscience Letters 503:3, pages 200-202.
Crossref
Crossref
M.A. Katzman, M. Vermani, L. Jacobs, M. Marcus, B. Kong, S. Lessard, W. Galarraga, L. Struzik & A. Gendron. (2008) Quetiapine as an adjunctive pharmacotherapy for the treatment of non-remitting generalized anxiety disorder: A flexible-dose, open-label pilot trial. Journal of Anxiety Disorders 22:8, pages 1480-1486.
Crossref
Crossref
Anjana Bose, Andrew Korotzer, Carl Gommoll & Dayong Li. (2008) Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder. Depression and Anxiety 25:10, pages 854-861.
Crossref
Crossref
Sohita Dhillon, Lesley J Scott & Greg L Plosker. (2006) Escitalopram. CNS Drugs 20:9, pages 763-790.
Crossref
Crossref